First of all, the centre is being designed and set up with a cell-based biologics vaccine platform, one that we believe when we're going to look at collaborating with vaccine sponsors is the basis in terms of making sure that their vaccine platform is aligned with a vaccine platform that is being built for the centre. That's one point.
With respect to Providence, I think what I would say is that I would have to defer to our colleagues at Innovation, Science and Economic Development. They are developing a biomanufacturing strategy. We're one part of the strategy. We're going to be here to collaborate with vaccine sponsors that can help us in being ready for any pandemic emergency to produce cell-based biologics vaccines.